Treatment of Atrial Fibrillation in the ICU

Initial Assessment and Stabilization

The American College of Cardiology and European Heart Society recommend that hemodynamically unstable patients with atrial fibrillation in the ICU undergo immediate synchronized electrical cardioversion, while stable patients should receive rate control as the initial management strategy, with first-line agents including IV beta-blockers or non-dihydropyridine calcium channel blockers 1, 2, 3
Before initiating therapy, it is crucial to identify and treat reversible causes, including sepsis, fluid overload, electrolyte abnormalities, hyperthyroidism, and acute coronary syndrome, as addressing these underlying issues may resolve atrial fibrillation without the need for antiarrhythmic therapy 2

For patients with preserved left ventricular function, the American College of Cardiology recommends IV beta-blockers, such as metoprolol or esmolol, as first-line therapy for rate control, due to their effectiveness in slowing ventricular response in the acute setting without pre-excitation 1, 2
The European Heart Society suggests that IV non-dihydropyridine calcium channel blockers, such as diltiazem or verapamil, are equally effective alternatives for rate control in patients with preserved left ventricular function 1, 2
For patients with reduced left ventricular function or decompensated heart failure, the American Heart Association recommends using IV beta-blockers cautiously, while IV digoxin or IV amiodarone are recommended to acutely control heart rate in this population, due to their ability to provide rate control without exacerbating heart failure 4

The European Heart Society recommends a lenient rate control strategy, targeting a resting heart rate of less than 110 bpm, as the initial target for most ICU patients, due to its association with reduced morbidity and mortality 2
A stricter rate control strategy, targeting a resting heart rate of less than 80 bpm, should be reserved for patients with continuing atrial fibrillation-related symptoms or suspected tachycardia-induced cardiomyopathy, as it may improve outcomes in these high-risk patients 2

The American College of Cardiology recommends electrical cardioversion for hemodynamically unstable patients with new-onset atrial fibrillation, as well as for patients with acute coronary syndrome and intractable ischemia despite rate control, due to its ability to rapidly restore sinus rhythm and improve hemodynamics 1, 2, 5
Pharmacological cardioversion should generally be deferred in the ICU setting unless atrial fibrillation duration is clearly less than 48 hours, due to the increased risk of thromboembolic events, and should only be attempted after assessing stroke risk using the CHA₂DS₂-VASc score and considering anticoagulation therapy 3, 5

In patients with acute coronary syndrome, the American College of Cardiology recommends IV beta-blockers to reduce myocardial oxygen demand, while IV amiodarone or digoxin may be considered with severe left ventricular dysfunction, heart failure, or hemodynamic instability, due to their ability to provide rate control and improve outcomes in these high-risk patients 4, 5
In patients with pre-excitation syndromes, such as Wolff-Parkinson-White syndrome, the American Heart Association recommends avoiding AV nodal blocking agents, such as adenosine, digoxin, and beta-blockers, due to their potential to accelerate ventricular rate and precipitate ventricular fibrillation, and instead using IV procainamide or ibutilide for rate control 1, 4
In patients with pulmonary disease, such as COPD, the European Heart Society recommends using non-dihydropyridine calcium channel blockers, such as diltiazem or verapamil, instead of beta-blockers, due to their ability to provide rate control without exacerbating respiratory symptoms 4
In patients with thyrotoxicosis, the American Thyroid Association recommends using beta-blockers to control heart rate, unless contraindicated, due to their ability to reduce sympathetic activity and improve outcomes in these patients 4

The European Heart Society recommends assessing stroke risk using the CHA₂DS₂-VASc score once the patient stabilizes, and considering anticoagulation therapy based on this assessment, due to the increased risk of thromboembolic events in patients with atrial fibrillation 2

The American College of Cardiology recommends avoiding the combination of IV beta-blockers and IV non-dihydropyridine calcium channel blockers, due to the risk of severe bradycardia and heart block, and instead using alternative agents, such as IV amiodarone or digoxin, for rate control in patients with contraindications to these agents 1
The American Heart Association recommends avoiding the use of dronedarone for rate control in permanent atrial fibrillation or in critically ill patients, due to its potential to exacerbate heart failure and increase mortality, and instead using alternative agents, such as IV beta-blockers or non-dihydropyridine calcium channel blockers, for rate control in these patients 1